GHRP-2 vs Myostatin Propeptide

Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a). Commonly stacked with GHRH analogs such as CJC-1295 or Sermorelin to amplify GH output synergistically.

GHRP-2 (growth hormone-releasing peptide-2; pralmorelin; KP-102) is a synthetic hexapeptide (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) and potent ghrelin receptor (GHS-R1a) agonist developed as a GH secretagogue with established efficacy in stimulating pulsatile GH release from pituitary somatotrophs, characterized by potent GH stimulation alongside non-selective co-stimulation of cortisol and prolactin secretion. As a first-generation GHRP, GHRP-2 achieves its GH-secretory effect through direct GHS-R1a agonism with amplification by endogenous GHRH; it is distinguished from later selective GHRPs such as ipamorelin by its non-selective endocrine profile, and synergistic GH stimulation is observed when combined with GHRH analogs in diagnostic protocols. GHRP-2 has been validated as a diagnostic agent for the GHRP-2 stimulation test used in Japan to assess GH secretion capacity in adults with suspected hypopituitarism or post-surgical pituitary dysfunction, with published human clinical data supporting its reliability as a GH stimulation tool in endocrine diagnostic practice. GHRP-2 has no FDA approval for any therapeutic or diagnostic indication in the United States; it is used diagnostically in Japan and as a research compound elsewhere, with no approved indication for GH enhancement, performance, or anti-aging applications, and its non-selective endocrine stimulation profile represents a relevant consideration versus more selective GH secretagogues. GHRP-2 dosage in research contexts: doses of 100–300 mcg per subcutaneous injection are documented across research protocols, typically administered 2–3 times daily. Co-administration with a GHRH analog (such as CJC-1295 or sermorelin) produces synergistic GH release and is studied in combination protocols for this reason. Administration is by subcutaneous injection following reconstitution with bacteriostatic water. GHRP-2 vs GHRP-6 vs ipamorelin: GHRP-2 produces potent GH release but with co-stimulation of cortisol and prolactin, similar to GHRP-6. The key distinguishing feature of GHRP-6 is stronger appetite stimulation (ghrelin-like effect); GHRP-2 produces less appetite stimulation with comparable or slightly greater GH output per dose. Both are non-selective compared to ipamorelin, which was developed specifically to achieve GH stimulation without the cortisol and prolactin co-elevation that characterizes first-generation GHRPs. For research contexts prioritizing GH selectivity, ipamorelin is generally preferred; GHRP-2 is used where its diagnostic validation and potent GH stimulation profile are the research objectives.

Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition

Myostatin propeptide is the endogenous N-terminal prodomain of the precursor myostatin protein (GDF-8) that, following cleavage of the mature myostatin dimer, remains non-covalently associated with it as a latency-associated complex, maintaining the active growth factor in an inactive state until proteolytic activation by BMP-1/tolloid family metalloproteinases releases it to engage ActRIIB receptors and signal through the Smad2/3 pathway. Recombinant versions of the propeptide can act as endogenous-mechanism inhibitors of myostatin by sequestering the mature peptide in an inactive complex, reducing the inhibitory signaling that myostatin exerts on skeletal muscle protein synthesis and satellite cell activity in the ActRII/Smad pathway. Foundational rodent studies demonstrate that overexpression of the myostatin propeptide produces significant skeletal muscle hypertrophy, and the BMP-1/tolloid proteolytic activation mechanism of the propeptide-myostatin latent complex has been characterized genetically in mouse models. Myostatin propeptide is a research compound with no regulatory approval in any jurisdiction; recombinant propeptide administration has not been evaluated in human clinical trials for muscle building or performance applications, and no human safety or pharmacokinetic data has been established.